These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 9185104

  • 21. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J.
    Hepatology; 1988; 8(5):1151-7. PubMed ID: 2971015
    [Abstract] [Full Text] [Related]

  • 22. [Fluid, electrolyte, and acid-base disorders in liver cirrhosis].
    Kinouchi T.
    Nihon Rinsho; 1994 Jan; 52(1):124-31. PubMed ID: 8114281
    [Abstract] [Full Text] [Related]

  • 23. Body fluid volume regulation in health and disease.
    Abraham WT, Schrier RW.
    Adv Intern Med; 1994 Jan; 39():23-47. PubMed ID: 8140955
    [Abstract] [Full Text] [Related]

  • 24. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D, Trägner P, Wawer A, Porst H, Daniel WG, Gross P.
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [Abstract] [Full Text] [Related]

  • 25. Fluid retention in cirrhosis: pathophysiology and management.
    Kashani A, Landaverde C, Medici V, Rossaro L.
    QJM; 2008 Feb; 101(2):71-85. PubMed ID: 18184668
    [Abstract] [Full Text] [Related]

  • 26. Use of diuretics in heart failure and cirrhosis.
    Schrier RW.
    Semin Nephrol; 2011 Nov; 31(6):503-12. PubMed ID: 22099507
    [Abstract] [Full Text] [Related]

  • 27. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis.
    Wong F, Liu P, Lilly L, Bomzon A, Blendis L.
    Clin Sci (Lond); 1999 Sep; 97(3):259-67. PubMed ID: 10464050
    [Abstract] [Full Text] [Related]

  • 28. Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis.
    López C, Jiménez W, Arroyo V, Clària J, La Villa G, Asbert M, Gaya J, Rivera F, Rodés J.
    Hepatology; 1991 Mar; 13(3):585-9. PubMed ID: 1999328
    [Abstract] [Full Text] [Related]

  • 29. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival?
    Gülberg V, Gerbes AL.
    Z Gastroenterol; 2002 Sep; 40(9):823-6. PubMed ID: 12215953
    [Abstract] [Full Text] [Related]

  • 30. Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis.
    Knotek M, Rogachev B, Schrier RW.
    Can J Gastroenterol; 2000 Nov; 14 Suppl D():112D-121D. PubMed ID: 11110623
    [Abstract] [Full Text] [Related]

  • 31. [The pathophysiology of ascites formation in cirrhosis of the liver].
    Benjaminov FS.
    Harefuah; 2002 Aug; 141(8):721-5, 760. PubMed ID: 12222138
    [Abstract] [Full Text] [Related]

  • 32. [Renal effects of the chronic inhibition of nitric oxide synthesis in cirrhotic rats with ascites].
    Ortiz MC, Fortepiani LA, Martínez-Salgado C, Eleno N, Atucha NM, López-Novoa JM, García-Estañ J.
    Nefrologia; 2001 Aug; 21(6):556-64. PubMed ID: 11881425
    [Abstract] [Full Text] [Related]

  • 33. [Pathophysiology of portal hypertension and mechanisms of sodium and water retention in cirrhosis].
    Garini G, Delsante M, Iannuzzella F.
    Recenti Prog Med; 2011 Mar; 102(3):134-40. PubMed ID: 21572486
    [Abstract] [Full Text] [Related]

  • 34. Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?
    Møller S, Henriksen JH.
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():31-41; discussion 42-3. PubMed ID: 15335398
    [Abstract] [Full Text] [Related]

  • 35. Unifying hypothesis of sodium and water regulation in health and disease.
    Schrier RW, Howard RL.
    Hypertension; 1991 Nov; 18(5 Suppl):III164-8. PubMed ID: 1937681
    [Abstract] [Full Text] [Related]

  • 36. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.
    Jiménez W, Gal CS, Ros J, Cano C, Cejudo P, Morales-Ruiz M, Arroyo V, Pascal M, Rivera F, Maffrand JP, Rodés J.
    J Pharmacol Exp Ther; 2000 Oct; 295(1):83-90. PubMed ID: 10991964
    [Abstract] [Full Text] [Related]

  • 37. Arachidonic acid derivatives and renal function in liver cirrhosis.
    Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P.
    Semin Nephrol; 1997 Nov; 17(6):530-48. PubMed ID: 9353864
    [Abstract] [Full Text] [Related]

  • 38. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1).
    Schrier RW.
    N Engl J Med; 1988 Oct 20; 319(16):1065-72. PubMed ID: 3050518
    [No Abstract] [Full Text] [Related]

  • 39. Pathophysiology of vasopressin in edematous disorders.
    Schrier RW, Howard RL.
    Nihon Naibunpi Gakkai Zasshi; 1989 Dec 20; 65(12):1311-27. PubMed ID: 2697604
    [Abstract] [Full Text] [Related]

  • 40. Nitric oxide and renal and cardiac dysfunction in cirrhosis.
    García-Estañ J, Ortiz MC, Lee SS.
    Clin Sci (Lond); 2002 Feb 20; 102(2):213-22. PubMed ID: 11834141
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.